Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
Maturitas|April 21, 2023
Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practiceNick Panay, Rossella E Nappi, Petra Stute, et al.Maturitas|May 2, 2026
Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women - Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled studyTommaso Simoncini, Céline Bouchard, Marie Cloes, et al.The Oncologist|February 1, 2013
A study to evaluate the cause of bone demineralization in gynecological cancer survivorsChara Stavraka, Kate Maclaran, Hani Gabra, et al.American Journal of Reproductive Immunology (New York, N.Y. : 1989)|February 16, 2008
Serial estimation of Th1:th2 cytokines profile in women undergoing in-vitro fertilization-embryo transferEmmanuel Kalu, Shree Bhaskaran, Meen Yau Thum, et al.Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|June 17, 2006
Complementary and hormonal therapy for vasomotor symptom relief: a conservative clinical approachLila E Nachtigall, Rodney J Baber, Ronald Barentsen, et al.Climacteric : the Journal of the International Menopause Society|August 7, 2025
Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USAJohn C Stevenson, Rodney Baber, Risa Kagan, et al.BJOG : an International Journal of Obstetrics and Gynaecology|September 1, 2025
Factors Associated With Non-Vasomotor Menopause Symptoms Experienced by 7285 Women: A UK-Wide National SurveyRhianna Davies, Ashwin Goyal, Zachary Nash, et al.Climacteric : the Journal of the International Menopause Society|September 12, 2025
The role of lifestyle medicine in menopausal health: a review of non-pharmacologic interventionsChika V Anekwe, Antonio Cano, Jennifer Mulligan, et al.Menopause (New York, N.Y.)|January 31, 2023
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)James A Simon, Richard A Anderson, Elizabeth Ballantyne, et al.The New England Journal of Medicine|November 7, 2008
Testosterone for low libido in postmenopausal women not taking estrogenSusan R Davis, Michele Moreau, Robin Kroll, et al.Pageof 10